Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

Leukemia

Volumn 29, Issue 5, 2015, Pages 1186-1194

  Paino T ^a,b   Paiva, B ^c   Sayagues J M ^b,d   Mota, I ^d   Carvalheiro, T ^e   Corchete, L A ^a,b   Aires Mejia I ^f   Perez J J ^f   Sanchez, M L ^d   Barcena, P ^d   Ocio, E M ^a,b,f   San Segundo, L ^a,b   Sarasquete, M E ^b,f   Garcia Sanz R ^b,f   Vidriales, M B ^b,f   Oriol, A ^g   Hernandez M T ^h   Echeveste, M A ⁱ   Paiva, A ^e   Blade, J ^j   Lahuerta, J J ^k   Orfao, A ^b,d   Mateos, M V ^b,f   Gutierrez N C ^b,f   San Miguel, J F ^c   more..

^a CSIC   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e IP   (Portugal)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

ⁱ HOSPITAL DONOSTIA   (Spain)

^j INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CHROMOSOME 1; CHROMOSOME DELETION; CLONOGENESIS; CONTROLLED STUDY; CYTOGENETICS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENETIC HETEROGENEITY; HUMAN; LIMIT OF DETECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PATIENT; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; STROMA CELL; TRISOMY; CELL SEPARATION; CLASSIFICATION; COCULTURE; CYTOLOGY; DISEASE COURSE; DRUG RESISTANCE; GENETICS; IMMUNOPHENOTYPING; PLASMA CELL; PROGNOSIS;

CELL SEPARATION; COCULTURE TECHNIQUES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIPLE MYELOMA; PHENOTYPE; PLASMA CELLS; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; STROMAL CELLS;

EID: 84929292795     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.321     Document Type: Article

References (35)

1. Mateos MV, San Miguel JF. How should we treat newly diagnosed multiple myeloma patients? Hematology Am Soc Hematol Educ Program 2013; 2013: 488-495.
2. McCarthy PL, Hahn T. Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology Am Soc Hematol Educ Program 2013; 2013: 496-503.
3. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122-1128.
4. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Comun 2014; 5: 2997.
5. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120: 1060-1066.
6. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120: 1067-1076.
7. Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 2014; 28: 384-390.
8. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014; 28: 384-390.
9. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 2012; 120: 1077-1086.
10. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91-101.
11. Magrangeas F, Avet-Loiseau H, Gouraud W, Lode L, Decaux O, Godmer P et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 2013; 27: 473-481.
12. Paiva B, Vidriales MB, Rosinol L, Martinez-Lopez J, Mateos MV, Ocio EM et al. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia 2013; 27: 2056-2061.
13. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-1975.
14. Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 26: 1986-2010.
15. Pedreira CE, Costa ES, Lecrevisse Q, van Dongen JJ, Orfao A. Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol 2013; 31: 415-425.
16. Fernandez C, Santos-Silva MC, Lopez A, Matarraz S, Jara-Acevedo M, Ciudad J et al. Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis. Leukemia 2013; 27: 2149-2156.
17. Gutierrez NC, Castellanos MV, Martin ML, Mateos MV, Hernandez JM, Fernandez M et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007; 21: 143-150.
18. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284.
19. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013; 121: 884-892.
20. Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol 2014; 165: 441-454.
21. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
22. Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L et al. Serum free light chain evaluation as a marker for the impact of intra-clonal heterogeneity on the progression and treatment resistance in multiple myeloma. Blood 2014; 123: 3414-3419.
23. Schmidt-Hieber M, Gutierrez ML, Perez-Andres M, Paiva B, Rasillo A, Tabernero MD et al. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. Haematologica 2013; 98: 279-287.
24. Mateo G, Castellanos M, Rasillo A, Gutierrez NC, Montalban MA, Martin ML et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005; 11: 3661-3667.
25. Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008; 26: 2737-2744.
26. Schmidt-Hieber M, Perez-Andres M, Paiva B, Flores-Montero J, Perez JJ, Gutierrez NC et al. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica 2011; 96: 328-332.
27. Rasillo A, Tabernero MD, Sanchez ML, Perez de Andres M, Martin Ayuso M, Hernandez J et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer 2003; 97: 601-609.
28. Bataille R, Jego G, Robillard N, Barille-Nion S, Harousseau JL, Moreau P et al. The phenotype of normal, reactive and malignant plasma cells. Identification of 'many and multiple myelomas' and of new targets for myeloma therapy. Haematologica 2006; 91: 1234-1240.
29. Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood 2013; 121: 318-328.
30. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013; 24: 289-304.
31. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
32. Paiva B, Paino T, Sayagues JM, Garayoa M, San-Segundo L, Martin M et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood 2013; 122: 3591-3598.
33. Hosen N, Matsuoka Y, Kishida S, Nakata J, Mizutani Y, Hasegawa K et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia 2012; 26: 2135-2141.
34. Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Fama R et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014; 123: 2139-2147.
35. Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28: 4630-4634.